Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms

Blood (2023) 141 (23): 2824–2840.

https://doi.org/10.1182/blood.2022015653

Published: 2023

Includes: Supplemental data

Journal Articles

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Blood (2022) 140 (Supplement 2): LBA-3.

https://doi.org/10.1182/blood-2022-171733

Published: 2022

Journal Articles

Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Sonia Jaramillo Segura, Maxi Wass, Judith Schaffrath, Kathrin Rieger, Axel Nogai, Mathias Haenel, Regina Herbst, Friedrich Stoelzel, Christoph Röllig, Edgar Jost, Richard F. Schlenk, Richard Noppeney, Christian H. Brandts, Utz Krug, Katharina S. Goetze, Sebastian Buske, Axel Florschütz, Jörg Schubert, Bernhard Opitz, Martin Mohren, Eva Eßeling, Stephan von Witzendorff, Marion Subklewe, Martin Kaufmann, Norbert Frickhofen, Christian W Scholz, Kerstin Schäfer-Eckart, Volker Kunzmann, Martin Schmidt-Hieber, Herbert G. Sayer, Andreas Rank, Philipp Hemmati, Frank Schueler, Simone Kowoll, Marina Scheller, Jörg Steighardt, Bayram Edemir, Lutz Peter Mueller, Irit Gliko-Kabir, Beatrice Ludwig-Kraus, Sabine Edemir, Ella Sorani, Mascha Binder, Abi Vainstein, Shaul Kadosh, Cora Gromann, Andreas Wienke, Claudia D. Baldus, Uwe Platzbecker, Hubert Serve, Martin Bornhaeuser, Christian Junghanss, Carsten Mueller-Tidow

Blood (2022) 140 (Supplement 1): 3338–3340.

https://doi.org/10.1182/blood-2022-166748

Published: 2022

Journal Articles

Treatment of Patients with Relapsed or Refractory Primary CNS Lymphoma (rrPCNSL) Enrolled in the Randomized Trials of the International Extranodal Lymphoma Study Group (IELSG)

Blood (2021) 138 (Supplement 1): 1417.

https://doi.org/10.1182/blood-2021-147822

Published: 2021

Journal Articles

A Phase II Study to Investigate the Efficacy and Safety of Eltrombopag in Combination with Dexamethasone As First-Line Treatment in Adults Patients with Newly Diagnosed Primary ITP (XPAG-ITP)

Mascha Binder, Axel Matzdorff, Falk Nimmerjahn, Mathias Rummel, Oliver Meyer, Tamara Tesanovic, Tanja Sauer

Blood (2021) 138 (Supplement 1): 3151.

https://doi.org/10.1182/blood-2021-147218

Published: 2021

Journal Articles

A Phase II Study to Investigate the Efficacy and Safety of Eltrombopag in Combination with Dexamethasone As First-Line Treatment in Adult Patients with Newly Diagnosed Primary ITP (XPAG-ITP)

Axel Matzdorff, MDPhD, Mascha Binder, MD, Falk Nimmerjahn, PhD, Oliver Meyer, MD PhD, Mathias J. Rummel, MD PhD, Tamara Tesanovic, PhD, Tanja Sauer

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-134318

Published: 2020

Journal Articles

Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS

Sonja Loges, MD, PhD, Michael Heuser, MD, Joerg Chromik, Carlos E Vigil, MD, Peter Paschka, MD, Isabel Ben-Batalla, PhD, Nuray Akyüz, David Micklem, Robert Holt, Anthony Brown, James Lorens, Murray Yule, Maxim Kebenko, MD, Melanie Janning, Mascha Binder, MD, Walter Fiedler, MD, Jorge E. Cortes, MD, Bjorn Gjertsen, MD PhD

Blood (2018) 132 (Supplement 1): 2672.

https://doi.org/10.1182/blood-2018-99-120380

Published: 2018

Journal Articles

Minimal Residual Disease (MRD) Analysis Using Multiparametric Flow Cytometry (MFC) and Identification of Differences in Subpopulations Using Next Generation Sequencing (NGS) in the Bone Marrow (BM) of Multiple Myeloma (MM) Patients (pts)

Sandra M. Dold, MSc, BSc, Veronika Riebl, Dagmar Wider, Marie Follo, PhD, Stefan J. Mueller, Ingrid Bartsch, Milena Pantic, PhD, Cornelius Miething, MD, Chrissoula Kiote-Schmidt, K. Martin Kortüm, MD, Mihaela Zlei, Abdel Kareem Azab, PhD, Mascha Binder, MD, Justyna Rawluk, Justus Duyster, Prof., Robert Zeiser, MD, Ralph Wäsch, MD, Monika Engelhardt, MD

Blood (2018) 132 (Supplement 1): 3222.

https://doi.org/10.1182/blood-2018-99-112489

Published: 2018

Journal Articles

The phosphotyrosine phosphatase SHP2 promotes anergy in chronic lymphocytic leukemia

Simon Schliffke, Sophia Buhs, Sarah Bolz, Helwe Gerull, Lisa von Wenserski, Kristoffer Riecken, Boris Fehse, Peter Nollau, Mascha Binder

Blood (2018) 131 (15): 1755–1758.

https://doi.org/10.1182/blood-2017-06-788166

Published: 2018

Includes: Supplemental data

Journal Articles

The Orally Available Selective Axl Inhibitor BGB324 Induces Diversification of the Immune Repertoire and Specific Changes in Plasma Biomarker Profiles

Sonja Loges, MD PhD, Bjørn Tore Gjertsen, Michael Heuser, MD, Joerg Chromik, Isabel Ben-Batalla, Nuray Akyüz, David Micklem, Anthony Brown, James Lorens, Murray Yule, Maxim Kebenko, MD, Melanie Janning, Mascha Binder, MD, Walter Fiedler, MD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 1375.

https://doi.org/10.1182/blood.V130.Suppl_1.1375.1375

Published: 2017

Journal Articles

Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking

Friederike Braig, Anna Brandt, Mariele Goebeler, Hans-Peter Tony, Anna-Katharina Kurze, Peter Nollau, Thomas Bumm, Sebastian Böttcher, Ralf C. Bargou, Mascha Binder

Blood (2017) 129 (1): 100–104.

https://doi.org/10.1182/blood-2016-05-718395

Published: 2017

Includes: Supplemental data

Journal Articles

Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation Options after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (PCNSL): Results of the Second Randomization of the IELSG32 Trial

Andrés J.M. Ferreri, MD, Kate Cwynarski, MBBS, FRPATH, PhD, Elisa Jacobsen Pulczynski, MD, Christopher P. Fox, MBChB, PhD, Elisabeth Schorb, MD, Paul La Rosée, MD, Mascha Binder, MD, Alberto Fabbri, MD, Valter Torri, MD, Eleonora Minacapelli, MD, Monica Falautano, MD, Fiorella Ilariucci, MD, Achille Ambrosetti, MD, Alexander Röth, MD, Claire Jane Hemmaway, MD, Peter M Johnson, MA, MD, Kim Linton, MBChB, MRCP, PhD, Tobias Pukrop, MD, Jette Sonderskov Gorlov, MD, Monica Balzarotti, MD, Georg Hess, MD, Ulrich Keller, MD, Stephan Stilgenbauer, MD, Jens P. Panse, MD, Alessandra Tucci, MD, Lorella Orsucci, MD, Francesco Pisani, MD, Alessandro Levis, MD, Stefan W. Krause, MD, Hans-Joachim Schmoll, MD PhD, Bernd Hertenstein, MD, Mathias Rummel, MD PhD, Jeffery Smith, MD, Michael Pfreundschuh, MD, PhD, Giuseppina Cabras, MD, Francesco Angrilli, MD, Maurilio Ponzoni, MD, Martina Deckert, MD, Letterio S. Politi, MD, Jurgen Finke, MD, Michele Reni, MD, Franco Cavalli, Emanuele Zucca, Gerald Illerhaus, MD

Blood (2016) 128 (22): 511.

https://doi.org/10.1182/blood.V128.22.511.511

Published: 2016

Journal Articles

BGB324, an Orally Available Selective Axl Inhibitor Exerts Anti-Leukemic Activity in the First-in-Patient Trial BGBC003 and Induces Unique Changes in Biomarker Profiles

Loges Sonja, Bjorn T. Gjertsen, Michael Heuser, Jörg Chromik, Isabel Ben Batalla, Nuray Akyüz, PhD, David Micklem, Anthony Brown, Jim Lorens, Maxim Kebenko, Melanie Janning, Mascha Binder, MD, Walter Fiedler, MD, Jorge E. Cortes, MD

Blood (2016) 128 (22): 592.

https://doi.org/10.1182/blood.V128.22.592.592

Published: 2016

Journal Articles

High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for Relapsed or Refractory Primary CNS Lymphoma - a Prospective Multicentre Trial By the German Cooperative PCNSL Study Group

Blood (2016) 128 (22): 781.

https://doi.org/10.1182/blood.V128.22.781.781

Published: 2016

Journal Articles

Opposite Effects of Bruton Tyrosine Kinase (BTK) Inhibitor Therapy with Ibrutinib and FCR Chemo-Immunotherapy on the Normal B Lymphocyte Repertoire in Patients with Chronic Lymphocytic Leukemia

Simon Schliffke, MD, Mariela Sivina, PhD, Ekaterina Kim, PhD, Benjamin Thiele, MD, Nuray Akyüz, PhD, Clemens Falker-Gieske, PhD, Toni Thenhausen, Artus Krohn-Grimberghe, PhD, Carsten Bokemeyer, MD, Nitin Jain, MD, Zeev Estrov, MD, Alessandra Ferrajoli, MD, William G. Wierda, MD PhD, Michael J. Keating, MD, Jan A. Burger, MD PhD, Mascha Binder, MD

Blood (2016) 128 (22): 4402.

https://doi.org/10.1182/blood.V128.22.4402.4402

Published: 2016

Journal Articles

A transplant “immunome” screening platform defines a targetable epitope fingerprint of multiple myeloma

Aneta Schieferdecker, Anna Oberle, Benjamin Thiele, Fabian Hofmann, Markus Göthel, Sebastian Miethe, Michael Hust, Friederike Braig, Mareike Voigt, Ute-Marie von Pein, Friedrich Koch-Nolte, Friedrich Haag, Malik Alawi, Daniela Indenbirken, Adam Grundhoff, Carsten Bokemeyer, Ulrike Bacher, Nicolaus Kröger, Mascha Binder

Blood (2016) 127 (25): 3202–3214.

https://doi.org/10.1182/blood-2015-10-676536

Published: 2016

Includes: Supplemental data

Journal Articles

BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant

Blood (2014) 124 (21): 4512.

https://doi.org/10.1182/blood.V124.21.4512.4512

Published: 2014

Journal Articles

B-Cell Receptors of Primary Central Nervous System Lymphoma Recognize Antigens in the Brain

Martin Trepel, Fabian Müller, Gerald Illerhaus, MD, Markus Glatzel, Mascha Binder, Elmar Spies

Blood (2014) 124 (21): 3003.

https://doi.org/10.1182/blood.V124.21.3003.3003

Published: 2014

Journal Articles

Next-generation sequencing of peripheral B-lineage cells pinpoints the circulating clonotypic cell pool in multiple myeloma

Benjamin Thiele, Marie Kloster, Malik Alawi, Daniela Indenbirken, Martin Trepel, Adam Grundhoff, Mascha Binder

Blood (2014) 123 (23): 3618–3621.

https://doi.org/10.1182/blood-2014-02-556746

Published: 2014

Includes: Supplemental data

Journal Articles

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma

Blood (2013) 122 (14): 2443–2452.

https://doi.org/10.1182/blood-2013-03-491431

Published: 2013

Includes: Supplemental data

NARROW

Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Treatment of Patients with Relapsed or Refractory Primary CNS Lymphoma (rrPCNSL) Enrolled in the Randomized Trials of the International Extranodal Lymphoma Study Group (IELSG)

A Phase II Study to Investigate the Efficacy and Safety of Eltrombopag in Combination with Dexamethasone As First-Line Treatment in Adults Patients with Newly Diagnosed Primary ITP (XPAG-ITP)

A Phase II Study to Investigate the Efficacy and Safety of Eltrombopag in Combination with Dexamethasone As First-Line Treatment in Adult Patients with Newly Diagnosed Primary ITP (XPAG-ITP)

Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS

Minimal Residual Disease (MRD) Analysis Using Multiparametric Flow Cytometry (MFC) and Identification of Differences in Subpopulations Using Next Generation Sequencing (NGS) in the Bone Marrow (BM) of Multiple Myeloma (MM) Patients (pts)

The phosphotyrosine phosphatase SHP2 promotes anergy in chronic lymphocytic leukemia

The Orally Available Selective Axl Inhibitor BGB324 Induces Diversification of the Immune Repertoire and Specific Changes in Plasma Biomarker Profiles

Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking

BGB324, an Orally Available Selective Axl Inhibitor Exerts Anti-Leukemic Activity in the First-in-Patient Trial BGBC003 and Induces Unique Changes in Biomarker Profiles

High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for Relapsed or Refractory Primary CNS Lymphoma - a Prospective Multicentre Trial By the German Cooperative PCNSL Study Group

Opposite Effects of Bruton Tyrosine Kinase (BTK) Inhibitor Therapy with Ibrutinib and FCR Chemo-Immunotherapy on the Normal B Lymphocyte Repertoire in Patients with Chronic Lymphocytic Leukemia

A transplant “immunome” screening platform defines a targetable epitope fingerprint of multiple myeloma

BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant

B-Cell Receptors of Primary Central Nervous System Lymphoma Recognize Antigens in the Brain

Next-generation sequencing of peripheral B-lineage cells pinpoints the circulating clonotypic cell pool in multiple myeloma

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only